Thyroid cancer

Maria E. Cabanillas; David G. McFadden; Cosimo Durante

doi:10.1016/S0140-6736(16)30172-6

Thyroid cancer

Maria E. Cabanillas, David G. McFadden, Cosimo Durante

Research output: Contribution to journal › Review article › peer-review

1009 Scopus citations

Abstract

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

Original language	English (US)
Pages (from-to)	2783-2795
Number of pages	13
Journal	The Lancet
Volume	388
Issue number	10061
DOIs	https://doi.org/10.1016/S0140-6736(16)30172-6
State	Published - Dec 3 2016

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(16)30172-6

Cite this

@article{53a90711cd1c4169a19e520ecd0d2b59,

title = "Thyroid cancer",

abstract = "Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.",

author = "Cabanillas, {Maria E.} and McFadden, {David G.} and Cosimo Durante",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2016",

month = dec,

day = "3",

doi = "10.1016/S0140-6736(16)30172-6",

language = "English (US)",

volume = "388",

pages = "2783--2795",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10061",

}

TY - JOUR

T1 - Thyroid cancer

AU - Cabanillas, Maria E.

AU - McFadden, David G.

AU - Durante, Cosimo

PY - 2016/12/3

Y1 - 2016/12/3

N2 - Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

AB - Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84970004218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970004218&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)30172-6

DO - 10.1016/S0140-6736(16)30172-6

M3 - Review article

C2 - 27240885

AN - SCOPUS:84970004218

SN - 0140-6736

VL - 388

SP - 2783

EP - 2795

JO - The Lancet

JF - The Lancet

IS - 10061

ER -

Thyroid cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this